How to Value a Veterinary Laboratory or Diagnostics Business

Veterinary diagnostics is one of those sectors where the market structure tells you almost everything you need to know about valuation. IDEXX Laboratories and Antech Diagnostics (owned by Mars) control roughly 70% of the reference lab market between them. Yet independent regional labs continue to operate, and some are building significant value — particularly those that have carved out specialty niches or locked in dense practice networks.

I've worked on several veterinary healthcare transactions, and diagnostics businesses consistently surprise sellers with their complexity. The valuation mechanics are different from a veterinary practice, different from a human diagnostics lab, and heavily influenced by the technology platform powering the operation. Let me walk through how this actually works.

The Market Reality: Two Giants and Everyone Else

Understanding veterinary diagnostics valuation requires understanding the competitive landscape. IDEXX and Antech aren't just competitors — they're the gravitational centers of the industry. Both operate massive reference lab networks, manufacture in-clinic analyzers, and offer practice management software integration. Their scale advantages in logistics, test menu breadth, and turnaround time are formidable.

So why do independent labs have value? Three reasons. First, regional density. A lab that serves 200 practices within a 100-mile radius can offer same-day results that even IDEXX struggles to match from a centralized facility. Second, relationships. Veterinarians are relationship-driven buyers, and a lab owner who visits practices personally builds loyalty that a corporate sales rep can't replicate. Third, specialty capabilities — cytology, histopathology, dermatopathology — where board-certified pathologists are the product, not the equipment.

What the Data Shows

Across 317 laboratory services transactions in our database, median multiples run 12.7x EBITDA and 2.3x revenue. For the $5-25M enterprise value bracket — where most independent veterinary labs transact — the median drops to 8.46x EBITDA. These are healthy multiples that reflect the recurring nature of diagnostic revenue and the attractive margin profile of well-run labs.

The sector trend is consolidating, which generally supports multiples. When strategic buyers (IDEXX, Antech, Heska) and PE platforms are actively acquiring, sellers have leverage. But the window matters — consolidation waves don't last forever, and the best time to sell is while multiple buyers are competing for assets.

Sample Volume: The Core Metric

If there's one number that defines a veterinary diagnostic lab's value, it's monthly sample volume. Not revenue, not profit — samples processed. Every buyer I've worked with starts here because sample volume is the leading indicator that drives everything else.

Here's why it matters more than revenue. A lab processing 15,000 samples per month at a $12 average revenue per test generates $180K in monthly revenue. But a lab processing the same 15,000 samples with a broader test menu averaging $18 per test generates $270K — same operational footprint, 50% more revenue. Buyers look at sample volume to understand the base, then evaluate revenue-per-test as the optimization lever.

The metrics buyers track around volume:

• Monthly sample volume and trend: Growing, stable, or declining? A 5-10% annual volume growth rate signals a healthy, expanding practice network.
• Revenue per test: Varies enormously by test mix. Basic chemistry panels run $8-15, while histopathology can be $80-200. Higher average RVT signals a more valuable test mix.
• Samples per practice: Average monthly submissions per client practice. More samples per practice means deeper integration and higher switching costs.
• Practice count and retention rate: How many practices submit regularly, and what percentage remain active year-over-year?

The Technology Platform: LIS Integration Matters

A veterinary lab's Laboratory Information System (LIS) and its integration with practice management software (Cornerstone, AVImark, eVetPractice) is increasingly a valuation driver. Why? Because integration creates switching costs.

When a veterinary practice can order tests, receive results, and auto-populate patient records without leaving their PMS, that's a workflow they won't voluntarily disrupt. I've seen practices stay with a regional lab for years despite IDEXX offering lower pricing, purely because the integration works and switching would mean retraining staff.

Labs that have invested in digital pathology — the ability to share slide images remotely for specialist consultation — are positioned particularly well. This technology enables a regional lab to offer subspecialty reads (dermatopathology, clinical pathology) without employing every type of board-certified pathologist in-house.

Point-of-Care vs. Reference Lab: Two Different Businesses

The veterinary diagnostics market has two segments that look similar from the outside but have completely different economics.

Reference laboratories receive samples from veterinary practices, process them centrally, and return results. The business model is volume-driven with relatively fixed costs — a lab running at 60% capacity and one running at 90% capacity have similar fixed costs but dramatically different margins. Efficient reference labs achieve 30-40% EBITDA margins, which is why they attract premium multiples.

Point-of-care (POC) businesses sell or lease in-clinic analyzers and consumables to veterinary practices. This is more of a razor-and-blades model — the analyzer placement creates a recurring consumable revenue stream. POC businesses are valued more like recurring revenue companies, with emphasis on installed base, consumable attachment rate, and contract renewal rates.

Some independent labs operate both segments, which creates strategic value for acquirers looking to build a full-stack diagnostics offering.

What Drives Premium Multiples

After working on multiple diagnostics transactions, I've identified the characteristics that consistently push multiples to the top of the range:

• Board-certified veterinary pathologists on staff. Not contracted — employed. A pathologist who has relationships with referring veterinarians and provides consultative reads (not just results) is enormously valuable and hard to replace.
• Dense geographic coverage. A lab serving 300 practices within courier range can offer logistics (daily pickup, same-day results) that creates a genuine moat.
• Specialty test capabilities. Histopathology, cytology, immunohistochemistry, and molecular diagnostics carry higher margins and attract referrals from practices that send their routine work to IDEXX.
• Turnaround time guarantees. Practices care about speed. A lab that consistently delivers results in 6-12 hours for routine panels — and can prove it with data — has a competitive advantage worth paying for.
• AAHA compliance and quality certifications. American Animal Hospital Association standards and quality management systems signal operational maturity to buyers.

What Destroys Value in Diagnostic Labs

The red flags I watch for in veterinary diagnostics deals:

Key-person pathologist risk. If one pathologist reads 70% of your histopathology cases and has no employment agreement or non-compete, your specialty revenue is fragile. Buyers will discount heavily for this, and they should — I've seen similar dynamics in medical practices where provider departure risk destroyed deal value.

IDEXX/Antech dependency. Some smaller labs actually operate as overflow processors for the big two, handling tests that IDEXX sends out rather than runs in-house. If a significant portion of your volume comes from another lab rather than directly from practices, your revenue is one contract cancellation away from collapse.

Equipment obsolescence. Laboratory equipment has a useful life of 7-12 years. If your core analyzers are at end-of-life and you're looking at a $500K-$1M equipment refresh, buyers will deduct that from their offer. Invest in equipment maintenance and upgrades before going to market.

Declining volume trends. If sample volume has been flat or declining for two years, that signals either market share loss or practice attrition. Either is difficult to reverse and will suppress your multiple.

Preparing a Diagnostics Business for Sale

If you're considering a sale in the next 18-24 months, focus on these areas:

• Build your data room around sample metrics. Monthly volume, revenue per test, samples per practice, turnaround times, quality metrics. Buyers will request all of this — having it organized signals a well-managed operation.
• Lock in your pathologists. Employment agreements with reasonable non-competes and retention incentives. A pathologist who might leave post-acquisition is the #1 diligence concern in every diagnostics deal I've seen.
• Expand your test menu. Adding high-margin specialty tests (even through reference partnerships for rare tests) increases revenue per sample and demonstrates growth potential.
• Strengthen practice relationships. Document your top 50 practice relationships — who the decision-maker is, contract status, volume trend, and competitive threats. This is the customer base a buyer is purchasing.

The Bottom Line

Veterinary diagnostics businesses occupy an attractive niche: recurring revenue, high margins, essential services, and active consolidation. At a median 8.46x EBITDA for the $5-25M bracket, well-run labs are commanding serious multiples. But the range is wide, and the difference between a 6x and a 10x exit comes down to the fundamentals — pathologist depth, practice density, technology integration, and the ability to demonstrate that your sample volume will continue growing after you're no longer the one visiting practices every Thursday afternoon. Prepare accordingly, and the market will reward you.